{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:43:10Z","timestamp":1762000990037,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous clinical trials have demonstrated the efficacy and safety of the anti\u2010IgE monoclonal antibody omalizumab in chronic spontaneous urticaria (<jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content>) not responding to antihistamine treatment. The primary aim of our study was to describe the response patterns of patients with refractory <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content> treated with omalizumab in a real\u2010world clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of medical records of 20 patients with refractory <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content> was performed. Demographic, clinical, and laboratory features were retrieved and analyzed in correlation with treatment data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age of our patient population was 54.5 years, while the majority were females (15\/20 cases, 75%). Mean disease duration prior to omalizumab administration was 21.8 months. All patients had a history of chronic urticaria, refractory to high antihistamine and corticosteroid treatment, and responded favorably to omalizumab after administration of 1\u20135 doses of omalizumab; complete response was observed in 17\/20 patients (85%) and well\u2010controlled disease in the remaining 3\/20 patients (15%). In a subset of cases (6\/20, 30%), best response to omalizumab was achieved after interval administration of a 9\u2010day course of methylprednisolone (total dose of 188 mg). Late response to omalizumab (after three\u2010month treatment) was significantly correlated (<jats:italic>P<\/jats:italic> = 0.026) with shorter disease duration before initiation of omalizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the present series, omalizumab, either alone or in combination with a short\u2010term course of corticosteroids, was highly effective in resolution of refractory <jats:styled-content style=\"fixed-case\">CSU<\/jats:styled-content>. Furthermore, disease duration prior to omalizumab had a significant effect on timing of response.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.13935","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T06:36:43Z","timestamp":1517812603000},"page":"417-422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria"],"prefix":"10.1111","volume":"57","author":[{"given":"Nikolaos","family":"Syrigos","sequence":"first","affiliation":[{"name":"Allergy Department \u201cSotiria\u201d General Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Grapsa","sequence":"additional","affiliation":[{"name":"3rd Department of Medicine University of Athens School of Medicine Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zande","sequence":"additional","affiliation":[{"name":"Allergy Department \u201cSotiria\u201d General Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Tziotou","sequence":"additional","affiliation":[{"name":"Allergy Department \u201cSotiria\u201d General Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterini","family":"Syrigou","sequence":"additional","affiliation":[{"name":"Allergy Department \u201cSotiria\u201d General Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12313"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.036"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-015-0072-2"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2009.21.3.226"},{"key":"e_1_2_5_6_1","first-page":"577","article-title":"Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil)","volume":"57","author":"Silvares MR","year":"2011","journal-title":"Rev Assoc Med Bras"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06385.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12494"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02496.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.306"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.013"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1342"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02707.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01726.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.023"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.12.005"},{"key":"e_1_2_5_18_1","first-page":"S30","article-title":"Omalizumab normalizes levels of high affinity immunoglobulin E receptor\u2010positive skin mast cells in patients with chronic spontaneous urticaria: a randomized, double\u2010blind, placebo\u2010controlled study","volume":"134","author":"Metz M","year":"2014","journal-title":"J Invest Dermatol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2012.4.6.326"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.13935","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.13935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:25:10Z","timestamp":1695612310000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.13935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/ijd.13935"],"URL":"https:\/\/doi.org\/10.1111\/ijd.13935","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"type":"print","value":"0011-9059"},{"type":"electronic","value":"1365-4632"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"2017-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}